Posdinemab

Posdinemab (JNJ-63733657) is a humanized IgG1/κ monoclonal antibody that selectively targets phosphorylated tau (pT217) . Posdinemab specifically binds to the pT217+tau epitope rich in the proline domain, blocks tau protein aggregation and seed propagation, and promotes the clearance of extracellular tau species. Posdinemab reduces the levels of free and total p217+tau in cerebrospinal fluid, thereby inhibiting the pathological propagation of tau protein and the formation of neurofibrillary tangles. Posdinemab can be used for the study of progressive supranuclear palsy syndrome and Alzheimer's disease (AD), especially for prodromal or mild AD disease[1][2][3].

Product Specifications

CAS Number

[2517973-04-3]

Product Name Alternative

JNJ-63733657

UNSPSC

12352203

Target

Tau Protein

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/posdinemab.html

Purity

99.0

Solubility

10 mM in DMSO|H2O

Smiles

[Posdinemab]

Molecular Weight

(145.331 kDa)

References & Citations

[1]Galpern WR, et al. Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease. J Prev Alzheimers Dis. 2024;11 (6) :1592-1603.|[2]Bijttebier S, et al. Development of immunoprecipitation - two-dimensional liquid chromatography-mass spectrometry methodology as biomarker read-out to quantify phosphorylated tau in cerebrospinal fluid from Alzheimer disease patients. J Chromatogr A. 2021 Aug 16;1651:462299.|[3]Panza F, et al. Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies. Expert Opin Investig Drugs. 2023 Jul-Dec;32 (7) :625-634.